Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole

Biochemical Pharmacology

Volumn 53, Issue 4, 1997, Pages 531-538

  Pastrakuljic, Aleksandra ^a   Tang, Bing K ^a   Roberts, Eve A ^a   Kalow, Werner ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP1A1; CYP1A2; ethoxyresorufin; fluvoxamine; human; isosafrole; O deethylas e

Indexed keywords

ALPHA NAPHTHOFLAVONE; APIGENIN; CYTOCHROME P450 ISOENZYME; FLUVOXAMINE; ISOSAFROLE;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

CELL LINE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; LIVER; SAFROLE;

EID: 0031581817     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00769-1     Document Type: Article

References (23)

1. 1. Wrighton SA and Stevens JC, The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22: 1-21, 1992.
2. 2. Wrighton SA, Wandenbranden M, Stevens JC, Shipley LA and Ring BJ, In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 25: 453-484, 1993.
3. 3. Ioannides C and Parke DV, Induction of cytochrome P450 as an indicator of potential chemical carcinogenesis. Drug Metab Dispos 25: 488-501, 1993.
4. 4. Sesardic D, Pelkonen O, Pasasen M and Boobis AR, Differential expression and regulation of cytochrome P4501A gene subfamily in human tissues. Carcinogenesis 11: 1183-1188, 1990.
5. 5. Schweikl H, Taylor JA, Kitareewan S, Linco P, Nogerney D and Goldstein JA, Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3: 239-249, 1993.
6. 6. Yun C-H, Shimada T and Guengerich FP, Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res 52: 1868-1874, 1992.
7. 7. Ocuda T, Vesell SE, Plotkin E, Tarone R, Bast RC and Gelboin HV, Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes form monozygotic and dizygotic twins. Cancer Res 37: 3904-3911, 1977.
8. 8. Catteau A, Douriez E, Beaune P, Paisson N, Bonaiti-Pellie C and Laurent P, Genetic polymorphism of CYP1A1 (EROD) activity. Pharmacogenetics 5: 110-119, 1995.
9. 9. Valero R, Segura J and Torre R, Selective in vitro inhibition of hepatic oxidative metabolism by quinolones: 7-Ethoxyresorufin and caffeine as model substrates. J Pharm Pharmacol 43: 17-21, 1992.
10. 10. Penman BW, Liping C, Gelboin HV, Gonzalez FJ and Crespi CL, Development of a human lymphoblastoid cell line constitutively expressing human liver CYP1A1 cDNA: Substrate specificity with model substrates and promutagens. Carcinogenesis 15: 1931-1937, 1994.
11. 11. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO, Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265: 401-407, 1993.
12. 12. Chang TKH, Gonzalez FJ and Waxman DJ, Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311: 437-442, 1994.
13. 13. Clarke SE, Ayrton AD and Chenery RJ, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 6: 517-526, 1994.
14. 14. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE and Loft S, Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214, 1993.
15. 15. Spina E, Campo GM, Avenoso A, Pollicino MA and Caputi AP, Interaction between fluvoxamine and imipramine/ desipramine in four patients. Ther Drug Monit 14: 194-196, 1992.
16. 16. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J and Brosen K, Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br J Clin Pharmacol 39: 151-159, 1995.
17. 17. Roberts EA, Xie ZW, Yang S and Lipa J, Inducibility of enzyme activities associated with the cytochrome P450 1A family, ethoxyresorufin O-deethylase, and methoxyresorufin O-demethylase in human hepatocyte lines derived from normal liver tissue. Drug Metab Dispos 21: 56-61, 1993.
18. 18. Tyndale RF, Inaba T and Kalow W, Evidence in humans for variant alloenzymes of the nondeficient sparteine/debrisoquine monooxygenase in vitro. Drug Metab Dispos 17: 334-340, 1989.
19. 19. Roberts EA, Kohno Y, Pastrakuljic A, Tang BK and Kalow W, Phenacetin O-deethylase in novel human hepatocyte lines: Evidence for preservation of basal and inducible CYP1A2 in vitro. Hepatobgy 20: 187A, 1994.
20. 20. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich PF, Interindividual variation in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423, 1994.
21. 21. Guengerich FP and Shimada T, Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol 4: 391-407, 1991.
22. 22. Campbell ME, Grant DM, Tadanobu I and Kalow W, Biotransformation of caffeine, paraxantine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducibie cytochrome(s) P450 in human liver microsomes. Drug Metab Dispos 2: 237-249, 1987.
23. 23. Sutter TR, Tang YM, Hayes CL, Wo Y-YP, Jabs EW, Li X, Yin H, Cody CW and Greenless WF, Complete cDNA sequence of human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 269: 13092-13099, 1994.